首页/数据集/Dataset from A Phase IIIb, 24-week, Randomised, Placebo-controlled, Double-blinded, Efficacy and Safety Study of Linagliptin (BI 1356) in Black/African American Patients With Type 2 Diabetes With a MTT Sub-study

Dataset from A Phase IIIb, 24-week, Randomised, Placebo-controlled, Double-blinded, Efficacy and Safety Study of Linagliptin (BI 1356) in Black/African American Patients With Type 2 Diabetes With a MTT Sub-study

NIAID Data Ecosystem2026-05-10 收录

2型糖尿病药物临床试验

非洲裔美国人糖尿病研究

数据链接：

https://doi.org/10.25934/00003618 数据链接链接失效反馈

官方服务：

资源简介：

Study of linagliptin vs. placebo in Black/African American patients with T2DM with a MTT sub-study

应用场景：

创建时间：

2025-12-08

2型糖尿病药物临床试验

SGLT2抑制剂药理学

Introduction This randomized, double-blind, placebo-controlled, single and multiple ascending-dose study evaluated the pharmacodynamic effects and safety/tolerability of canagliflozin, a sodium glucos

NIAID Data Ecosystem50

Dataset from A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 100 mg qd or Metformin 1500 mg Daily in Elderly Drug Naive Patients With Type 2 Diabetes

2型糖尿病药物临床试验

老年患者疗效评估

This study is designed to demonstrate the efficacy and safety of vildagliptin compared to metformin in elderly drug naive patients with type 2 diabetes

NIAID Data Ecosystem00

Dataset from A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan

2型糖尿病药物临床试验

药物联合疗效评估

The purpose of this study was to evaluate the efficacy and safety of alogliptin, once daily (QD) combined with an α-glucosidase inhibitor taken three times daily (TID) in type 2 diabetic patients with

NIAID Data Ecosystem00

Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)

2型糖尿病药物临床试验

心血管风险评估

The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular

DataCite Commons2025-07-02 更新00

Available IPD datapackage for study 'A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin'

2型糖尿病药物临床试验

胰高血糖素样肽-1受体激动剂疗效评估

The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to metformin, over a period of 24 weeks of treatment, foll

DataCite Commons2024-12-02 更新00

Dataset from A Phase IIIb, 24-week, Randomised, Placebo-controlled, Double-blinded, Efficacy and Safety Study of Linagliptin (BI 1356) in Black/African American Patients With Type 2 Diabetes With a MTT Sub-study

资源简介：

相关数据集